ASCO24: AstraZeneca's armoured CAR-T shrinks liver tumours

2024-06-03

临床1期细胞疗法ASCO会议免疫疗法临床结果

Researchers unveiled some promising early clinical data on AstraZeneca's next-generation autologous CAR-T cell therapy C-CAR031, showing the experimental treatment could substantially reduce tumour burden in patients with advanced hepatocellular carcinoma (HCC).

C-CAR031 targets the GPC3 surface antigen, which is highly expressed in HCC, but largely absent from normal tissue. The "armoured" CAR-T construct was engineered to resist immunosuppressive signals like TGF-beta in the solid tumour microenvironment. AstraZeneca is partnered on the treatment with AbelZeta, which manufactures C-CAR031 in China.

The Phase I data from 22 efficacy evaluable patients, presented at the American Society of Clinical Oncology (ASCO) annual meeting on Monday, demonstrated an overall response rate of 50% across all dose levels in the Phase I dose-escalation study, including 11 partial responses (PRs) and 1 unconfirmed PR, according to an abstract of the study. At the highest dose level evaluated, 57.1% of patients achieved an objective response, including 4 PRs and 1 unconfirmed PR.

The 24 patients enrolled had GPC3+ advanced HCC GPC3+ advanced HCC that progressed after receiving at least one and a median of 3.5 prior lines of therapy, including immune checkpoint inhibitors and tyrosine kinase inhibitors in nearly all cases.

Researchers noted that over four-fifths of patients had extrahepatic metastases at baseline. They noted that tumour reductions were observed in 90.9% of patients, "not only in intrahepatic lesions, but also extrahepatic ones with a median reduction of 44%."

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构